Mabvax Therapeutics Holdings ("Mabvax") through its subsidiaries develops human antibody-based products and vaccines to address unmet medical needs for the treatment of diseases such as pancreatic, lung, sarcoma ovarian and breast cancer.

According to the law firm press release, the lawsuit alleges that MabVax and other Defendants made materially false and misleading statements and failed to disclose that: (1) the Company’s internal controls over financial reporting were materially weak and deficient; (2) the Company had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or the Company’s officers and directors by certain shareholders; and, (3) as a result of the foregoing, the Company’s financial statements and Defendants’ statements about MabVax’s business, operations, and prospects were materially false and misleading at all relevant times.

On September 6, 2018, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. The consolidated litigation shall be captioned "In re Mabvax Therapeutics Securities Litigation." Lead Plaintiff filed a consolidated Complaint on October 10.

This case was voluntarily dismissed on November 13, 2018.